Warm Autoimmune Hemolytic Anemia Market
As per DelveInsight, the Warm Autoimmune Hemolytic Anemia (WAIHA) market size was found to be USD 543 Million in 2021, which is anticipated to grow by 2032. Some of the key factors such as the number of Prevalent cases of Warm Autoimmune hemolytic anemia in the 7MM and the launch of emerging therapies is expected to create a significant shift in the overall market size during the forecast period (2022-2032).
Some of the leading pharma and biotech giants in the Warm Autoimmune Hemolytic Anemia therapeutics market include Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation, Annexon, and others.
DelveInsight’s ” [https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Warm Autoimmune Hemolytic Anemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Warm Autoimmune Hemolytic Anemia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Warm Autoimmune Hemolytic Anemia (WAIHA) Overview
Warm Autoimmune Hemolytic Anemia (wAIHA) is among the most prevalent autoimmune disorders and is predicted by the World Health Organization to become the leading cause of disease burden in high-income countries by 2032. Autoimmune hemolytic anemia (AIHA) is characterized by the accelerated destruction of red blood cells (RBCs) in the presence of autoantibodies against RBCs, with or without complement activation. These autoantibodies are produced by self-reactive B lymphocytes, both in tissue and circulation, with assistance from T helper lymphocytes.
wAIHA represents the most common form of autoimmune hemolytic anemia, accounting for approximately 70-80% of adult cases and around 50% of pediatric cases. Over half of these cases are classified as primary, with an undefined cause, while the remainder are secondary to conditions such as lymphoproliferative syndromes, malignant diseases like chronic lymphoblastic leukemia (CLL), non-Hodgkin’s lymphoma, and various solid tumors.
Currently, there are no approved therapies for managing wAIHA, with only one-third of the patients maintaining sustained disease control once steroids are discontinued.
Warm Autoimmune Hemolytic Anemia (WAIHA) Market Key Facts
*
The Warm Autoimmune Hemolytic Anemia market size in the seven major markets was found to be USD 545 million in 2022.
*
The total 7MM prevalent cases of Warm Autoimmune Hemolytic Anemia were 115,600+ cases in 2020.
*
Among the European countries, Germany reported the highest prevalent population of Warm Autoimmune Hemolytic Anemia, followed by France, whereas Spain accounted for the lowest number of cases in the 7MM as well as among the EU-5 countries.
*
The prevalent cases of Warm Autoimmune Hemolytic Anemia are expected to rise at a CAGR of 0.38% for the study period [2019-2032] in the 7MM.
*
Japan had 14,500+ diagnosed prevalent cases of Warm Autoimmune Hemolytic Anemia in 2021, which is expected to decline during the forecasted period [2022-2032].
[https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Warm Autoimmune Hemolytic Anemia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Warm Autoimmune Hemolytic Anemia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology Segmented by –
*
Prevalent Cases of Autoimmune Hemolytic Anemia (AIHA) in the 7MM [2019-2032]
*
Diagnosed Prevalent Cases of Warm Autoimmune Hemolytic Anemia (wAIHA) in the 7MM [2019-2032]
*
Prevalent Cases of Warm Autoimmune Hemolytic Anemia (wAIHA) in the 7MM [2019-2032]
*
Gender-specific Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia (wAIHA) in the 7MM [2019-2032]
*
Type-specific Diagnosed Prevalent Cases of Warm Autoimmune Hemolytic Anemia (wAIHA) in the 7MM [2019-2032]
Warm Autoimmune Hemolytic Anemia (WAIHA) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Warm Autoimmune Hemolytic Anemia market or expected to be launched during the study period. The analysis covers the Warm Autoimmune Hemolytic Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Warm Autoimmune Hemolytic Anemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Warm Autoimmune Hemolytic Anemia Market Will Evolve and Grow by 2032 @ [https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Warm Autoimmune Hemolytic Anemia (WAIHA) Therapeutics Analysis
There are several major pharma and biotech giants developing therapies for Warm Autoimmune Hemolytic Anemia. Rigel Pharmaceuticals, Immunovant Sciences GmbH, Apellis Pharmaceuticals are some of the leading companies in the therapeutics market with their Warm Autoimmune Hemolytic Anemia drug candidates in the mid to advanced stage of clinical development.
The Leading Companies in the Warm Autoimmune Hemolytic Anemia (WAIHA) therapeutics market include:
*
Immunovant Sciences GmbH
*
Apellis Pharmaceuticals, Inc.
*
Bioverativ
*
Rigel Pharmaceuticals
*
Johnson & Johnson
*
Sanofi
*
Incyte Corporation
*
Annexon
*
Rigel Pharmaceuticals
*
Bioverativ, a Sanofi company
*
Incyte Corporation
*
Sanofi
*
Johnson & Johnson
And Many Others
Warm Autoimmune Hemolytic Anemia (WAIHA) Drugs [https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] Covered in the Report Include:
*
Fostamatinib: Rigel Pharmaceuticals
*
BIV009: Bioverativ, a Sanofi company
*
Parsaclisib: Incyte Corporation
*
Rilzabrutinib: Sanofi
*
Nipocalimab: Johnson & Johnson
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ [https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Key Insights
2. Executive Summary
3. Warm Autoimmune Hemolytic Anemia Competitive Intelligence Analysis
4. Warm Autoimmune Hemolytic Anemia Market Overview at a Glance
5. Warm Autoimmune Hemolytic Anemia Disease Background and Overview
6. Warm Autoimmune Hemolytic Anemia Patient Journey
7. Warm Autoimmune Hemolytic Anemia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Warm Autoimmune Hemolytic Anemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Warm Autoimmune Hemolytic Anemia Unmet Needs
10. Key Endpoints of Warm Autoimmune Hemolytic Anemia Treatment
11. Warm Autoimmune Hemolytic Anemia Marketed Products
12. Warm Autoimmune Hemolytic Anemia Emerging Drugs and Latest Therapeutic Advances
13. Warm Autoimmune Hemolytic Anemia Seven Major Market Analysis
14. Attribute Analysis
15. Warm Autoimmune Hemolytic Anemia Market Outlook (In US, EU5, and Japan)
16. Warm Autoimmune Hemolytic Anemia Access and Reimbursement Overview
17. KOL Views on the Warm Autoimmune Hemolytic Anemia Market
18. Warm Autoimmune Hemolytic Anemia Market Drivers
19. Warm Autoimmune Hemolytic Anemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=warm-autoimmune-hemolytic-anemia-market-to-observe-significant-growth-during-the-forecast-period-rigel-pharmaceuticals-apellis-pharmaceuticals-inc-johnson-johnson-sanofi-incyte-corporation]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
